At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 28 enrolled
Drug / intervention
NGR-hTNF +1 moredrug
Likely dose
NGR-hTNF 0.8 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NGR007: A Phase II Study of NGR-hTNF Administered in Combination With Doxorubicin Every 3 Weeks in Patients Affected by Advanced or Metastatic Small Cell Lung Carcinoma (SCLC) Previously Treated With at Least One Therapeutic Regimen
In Brief
A Phase 2 clinical trial evaluating NGR-hTNF and Doxorubicin for Small Cell Lung Cancer. Completed, enrolled 28 participants across 5 sites.
Detailed Summary
The main objective of the trial is to document the progression free survival (PFS) in advanced or metastatic small cell lung carcinoma (SCLC) patients previously treated with at least one therapeutic regimen
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSmall Cell Lung Cancer
CountriesItaly
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2007
First PostedJun 2007
Primary CompletionSep 2010
Study CompletionMay 2011
TodayJul 2026
First PostedJun 7, 2007
Enrollment StartFeb 14, 2007
Primary CompletionSep 22, 2010
Study CompletionMay 17, 2011
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 19.1 years ago
Interventions
NGR-hTNFdrug
iv q3W 0.8 mcg/sqm NGR-hTNF
Doxorubicindrug
iv q3W 75 mg/sqm doxorubicin 60 minutes after NGR-hTNF infusion